Human Molecular Genetics Advance Access originally published online on February 5, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Molecular Genetics, 2004, Vol. 13, Review Issue 1 R91-R102
DOI: 10.1093/hmg/ddh074
Genetic dissection of myocilin glaucoma
1Osteoporosis Research Center, Creighton University Omaha, NE 68131, USA, 2Division of Ophthalmology, Creighton University, Omaha, NE 68131, USA and 3Office of the President, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
Primary open-angle glaucoma (POAG) is a complex disease with unknown causes. However, in the past decade, POAG has been linked to six chromosomal regions, of which the gene MYOC encoding myocilin and the gene OPTN encoding optineurin have been identified to harbor causal mutations (disease-causing variants, DCV). POAG caused by DCV at MYOC has been termed ‘myocilin glaucoma’. Clinically, DCV at MYOC may manifest as a typical POAG, normal tension glaucoma, or ocular hypertension without glaucoma. Individuals with the Arg46Stop mutation that almost knocks out the entire coding sequence may have severe glaucoma or no glaucoma. Genetically, myocilin glaucoma follows autosomal dominant, recessive or no pattern of inheritance. DCV at MYOC cause POAG in interaction with environmental factors and DCV at other loci. Most DCV at MYOC are relatively young, and the Gln368Stop mutation is exclusively European in origin. The overall frequency of DCV at MYOC is similar among African, Caucasian and Asian probands with POAG. Because of this fact and the higher prevalence of POAG in African descendants compared with Caucasians or Asians, the overall frequency of DCV at MYOC is several-fold higher in the general population of African descendants, which is in part responsible for their higher prevalence of POAG. Although the Arg46Stop mutation was often observed in normal controls, Arg46Stop carriers tend to have higher risk of developing POAG. Polymorphisms at several loci including MYOC are associated with POAG, and play an important role in the pathogenesis of POAG.
* To whom correspondence should be addressed at: Osteoporosis Research Center, Creighton University School of Medicine, 601 North 30th Street, Suite 6730, Omaha, NE 68131, USA. Tel: +1 4022804283; Fax: +1 4022805173; Email: gdgong{at}creighton.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.-S. Kwon, H.-S. Lee, Y. Ji, J. S. Rubin, and S. I. Tomarev Myocilin Is a Modulator of Wnt Signaling Mol. Cell. Biol., April 15, 2009; 29(8): 2139 - 2154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Zgaga, C Hayward, Z Vatavuk, G Bencic, T Zemunik, A Valkovic, I Valkovic-Antic, K Bucan, and I Rudan High prevalence of glaucoma in Veli Brgud, Croatia, is caused by a dominantly inherited T377M mutation in the MYOC gene Br J Ophthalmol, November 1, 2008; 92(11): 1567 - 1568. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhou, O. Grinchuk, and S. I. Tomarev Transgenic Mice Expressing the Tyr437His Mutant of Human Myocilin Protein Develop Glaucoma Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1932 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Shen, T. Koga, B.-C. Park, N. SundarRaj, and B. Y. J. T. Yue Rho GTPase and cAMP/Protein Kinase A Signaling Mediates Myocilin-induced Alterations in Cultured Human Trabecular Meshwork Cells J. Biol. Chem., January 4, 2008; 283(1): 603 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sanchez-Sanchez, F. Martinez-Redondo, J. D. Aroca-Aguilar, M. Coca-Prados, and J. Escribano Characterization of the Intracellular Proteolytic Cleavage of Myocilin and Identification of Calpain II as a Myocilin-processing Protease J. Biol. Chem., September 21, 2007; 282(38): 27810 - 27824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-C. Park, M. Tibudan, M. Samaraweera, X. Shen, and B. Y.J.T. Yue Interaction between two glaucoma genes, optineurin and myocilin Genes Cells, August 1, 2007; 12(8): 969 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Y. Wang, B. J. Fan, J. K. H. Chua, P. O. S. Tam, C. K. S. Leung, D. S. C. Lam, and C. P. Pang A Genome-wide Scan Maps a Novel Juvenile-Onset Primary Open-Angle Glaucoma Locus to 15q Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5315 - 5321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Funayama, Y. Mashima, Y. Ohtake, K. Ishikawa, N. Fuse, N. Yasuda, T. Fukuchi, A. Murakami, Y. Hotta, N. Shimada, et al. SNPs and Interaction Analyses of Noelin 2, Myocilin, and Optineurin Genes in Japanese Patients with Open-Angle Glaucoma Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5368 - 5375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Malyukova, H.-S. Lee, R. N. Fariss, and S. I. Tomarev Mutated Mouse and Human Myocilins Have Similar Properties and Do Not Block General Secretory Pathway Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 206 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Fan, D. Y. L. Leung, D. Y. Wang, S. Gobeil, V. Raymond, P. O. S. Tam, D. S. C. Lam, and C. P. Pang Novel Myocilin Mutation in a Chinese Family With Juvenile-Onset Open-Angle Glaucoma Arch Ophthalmol, January 1, 2006; 124(1): 102 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Grinchuk, Z. Kozmik, X. Wu, and S. Tomarev The Optimedin Gene Is a Downstream Target of Pax6 J. Biol. Chem., October 21, 2005; 280(42): 35228 - 35237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aung, V. H. K. Yong, P. T. K. Chew, S. K. L. Seah, G. Gazzard, P. J. Foster, and E. N. Vithana Molecular Analysis of the Myocilin Gene in Chinese Subjects with Chronic Primary-Angle Closure Glaucoma Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1303 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu and D. Vollrath Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma Hum. Mol. Genet., June 1, 2004; 13(11): 1193 - 1204. [Abstract] [Full Text] [PDF]
|
|